Overall Survival in Phase III SUNRISE Subgroup Receiving Subsequent Immune Checkpoint Inhibitors

os_km_sact_with_io_28febos

Modified from Kallinteris NL et. al., AACR 2017

Peregrine Pharmaceuticals Inc.
Format

PNG

Source

Peregrine Pharmaceuticals Inc.

Downloads